

### **Anti-Complement C5 Reference Antibody (eculizumab)**

Recombinant Antibody Catalog # APR10107

#### **Specification**

# Anti-Complement C5 Reference Antibody (eculizumab) - Product Information

Application Primary Accession Reactivity Clonality Isotype

Calculated MW

FC, E, FTA P01031

Human, Mouse Monoclonal IgG1

145.74 KDa

# Anti-Complement C5 Reference Antibody (eculizumab) - Additional Information

Target/Specificity Complement C5

**Endotoxin** 

< 0.001EU/ μg, determined by LAL method.

**Conjugation** Unconjugated

**Expression system** 

CHO Cell

**Format** 

Purified monoclonal antibody supplied in PBS, pH6.0, without preservative. This antibody is purified through a protein A column.

### Anti-Complement C5 Reference Antibody (eculizumab) - Protein Information

Name C5

Synonyms CPAMD4

#### **Function**

Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled.

**Cellular Location** 

Secreted.

## Anti-Complement C5 Reference Antibody (eculizumab) - Protocols









Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- <u>Immunohistochemistry</u>
- <u>Immunofluorescence</u>
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

# Anti-Complement C5 Reference Antibody (eculizumab) - Images



Anti-Complement C5 Reference Antibody (eculizumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-Complement C5 Reference Antibody (eculizumab)is more than 98.7% ,determined by SEC-HPLC.



